TLR9 and metabolic dysfunction-associated steatohepatitis: Of the handful of pathways listed that are directly targetable, differential activation of TLR9 and TLR9 signaling and adaptor proteins are all significantly associated with NASH disease severity, all with adjusted p-values of <0.0001.